Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathalie Vanlaer has a total of 132 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Rogiers

    3 shared publications
  • Bart Neyns

    Department of Medical Oncology, UZ Brussel, Brussels, Belgium

    3 shared publications
  • Iris Dirven

    Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium

    3 shared publications
  • A. Rogiers

    Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Translational Oncology Research Center (TORC), Team Laboratory for Medical and Molecular Oncology (LMMO), Brussels, Belgium; Department of Psychiatry, CHU Brugman, Brussels, Belgium

    2 shared publications
  • Anne Rogiers

    Centre Hospitalier Universitaire Brugmann, Brussels, Belgium

    2 shared publications
  • Bart Neyns

    Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

    2 shared publications

Latest Publications

  • Open Access

    International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100

    by Louis Fox, Marieke van Leeuwen, Jennifer M. Jones, Amal Al-Omari, Haneen Abaza, Muna Al-Khaifi, Martin Eichler, Sue Hartup, Galina Velikova, Nanna Friðriksdóttir, et al.


  • Open Access

    Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial

    by I. Dirven, C. Bertels, Y. Moreels, J.I. Kessels, N. Vanlaer, A.-S. Vander Mijnsbrugge, M. Vounckx, I. Dirks, L. Raes, X. Geeraerts, et al.

  • Open Access

    The Effectiveness of a Multidisciplinary Integrative Survivorship Program for Cancer-Related Cognitive Impairment: A Prospective Cohort Study

    by Nathalie Vanlaer, Camille Testaferrata, Lynn Decabooter, Iris Dirven, Cleo Bertels, Lara Stas, Sebastien Van Eycken, Matthieu Hein, Bart Neyns, Anne Rogiers

    Background: Cancer-related cognitive impairment (CRCI) affects quality of life, daily functioning and return-to-work. However, CRCI remains under-addressed in cancer care. Since cognitive complaints often co-occur with fatigue and psychological distress, a multimodal approach is warranted. We developed Integrative Neuro-Cognitive Remediation Therapy (INCRT), a multidisciplinary survivorship program combining personalized cognitive function and strategy training with group-based psychoeducation, cognitive–behavioral therapy and Acceptance and Commitment Therapy, and onco-yoga. Methods: Cancer survivors suffering from CRCI were eligible. Assessments included neuropsychological testing, patient-reported outcomes, and daily functioning at baseline (T0), post-intervention (T1), and 6-month follow-up (T2). Primary outcomes were objective and subjective neurocognitive functioning (NCF); secondary outcomes were psychological distress, fatigue, metacognition, and daily functioning. Changes were analyzed using linear mixed models. Results: Between November 2022 and January 2025, 44 of 56 eligible survivors enrolled; 38 completed the program (71.1% female; median age 53.5). Objective and subjective NCF improved significantly at T1 and T2 (ps < 0.001). Psychological distress, fatigue, and unhelpful metacognitions decreased over time (ps < 0.05). Participants reported greater emotional and cognitive insight and improved daily functioning. Conclusions: INCRT improves cognitive functioning, reduces psychological distress and fatigue, and enhances daily functioning, with benefits maintained at follow-up. The integrative design supports sustained effects by promoting internalization and daily application of learned strategies.

  • Open Access

    Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study

    by Nathalie Vanlaer, Iris Dirven, Bart Neyns, Anne Rogiers

    Background: There is a need for a better understanding of survivorship-related issues in advanced cancer survivors treated with immune checkpoint blockade (ICB). The purpose of this study was to identify survivorship-related issues, with a focus on psychological distress, cognitive complaints, physical sequelae, impact on family dynamics, and care needs in unresectable, advanced cancer survivors treated with ICB. Methods: Semi-structured interviews and patient-reported outcome measures (PROMs) were conducted in survivors followed up at the University Hospital Brussels. We performed content analysis on the semi-structured interviews and analyzed the PROMs descriptively. Results: 70 cancer survivors (71.4%) consented to participate between July 2022 and November 2023. Clinical fear of cancer recurrence (FCR) was present in 54.3% of the cancer survivors, and 18.6% had elevated cognitive complaints. We identified triggers related to clinically important psychological distress, such as immune-related adverse events, the progression/recurrence of disease, difficulties in adjusting to life after treatment, and co-existing life stressors, alongside persistent physical issues and unmet psychological and nutritional care needs. Conclusion: Our results indicate the existence of persistent psychological, physical, and cognitive issues, and support the need for routine screening for FCR. The identified triggers related to severe psychological distress can aid clinicians in timely referring the patient, thereby enhancing survivorship care.


  • Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition

    by Wietse Geens, Nathalie Vanlaer, Lynn Nijland, Sven Van Laere, Julia Katharina Schwarze, Michaël Bruneau, Bart Neyns, Anne Rogiers, Johnny Duerinck

    Purpose After glioblastoma (GB) recurrence, prognosis is very cumbersome. Therefore, health-related quality of life (HRQoL) and neurocognitive functioning (NCF) have become important endpoints in clinical trials when evaluating novel treatments. We aimed to evaluate the HRQoL and NCF in patients with recurrent glioblastoma (rGB) treated with a combination of surgical intervention (reoperation or biopsy) and intracerebral immune checkpoint inhibition. Methods Patients who participated in the trial (N = 23), at a single-center university hospital were included. Data were collected using 3 patient-reported outcome measures (EORTC-QLQ-C30, EORTC-QLQ-BN20, and HADS) and computerized NCF testing. In the responder group, baseline values were compared to results at a 6-month follow-up. Additionally, exploratory analyses compared baseline HRQoL and NCF between responders and non-responders. Results There were five responders and 18 non-responders. When comparing the mean and individual baseline with follow-up results for the responders, we observed overall a stable to slight clinically relevant improvement of HRQoL in multiple subsets of the questionnaires while maintaining a stable NCF. One patient deteriorated on anxiety and depression symptoms from baseline to follow-up. Conclusions In patients that responded to intracerebral immunotherapy in our institutional trial, HRQoL and NCF remained stable over time, suggesting that no detrimental effect on cognitive function or quality of life may be expected with this treatment approach. Furthermore, there seems to be an overall tendency for responders to score better on HRQoL and NCF than non-responders at baseline.


  • 1860P Objective and subjective neurocognitive functioning (NCF) in advanced cancer survivors treated with immune checkpoint blockade (ICB)

    by N. Vanlaer, I. Dirven, M. Vounckx, J. Tijtgat, M. Verhaert, S. Aspeslagh, L. Decoster, A. Rogiers, B. Neyns

  • Open Access

    Prevalence of Insomnia and Sleep Habits during the First and Second Wave of COVID-19 in Belgium

    by Aurore Roland, Clara Colomb, Stéphane Noël, Arcady Putilov, Halszka Oginska, Bérénice Delwiche, Oumaima Benkirane, Maxime Windal, Nathalie Vanlaer, Giovanni Briganti, et al.

    Belgium has one of the highest numbers of COVID-19 cases per 1 million inhabitants. The pandemic has led to significant societal changes with repercussions on sleep and on mental health. We aimed to investigate the effect of the first and the second wave of COVID-19 on the sleep of the Belgian populationWe launched two online questionnaires, one during the first lockdown (7240 respondents) and one during the second (3240 respondents), to test differences in self-reported clinical insomnia (as measured by the Insomnia Severity Index) and sleep habits during the two lockdowns in comparison with the pre-COVID period. The number of persons with clinical insomnia rose during the first lockdown (19.22%) and further during the second (28.91%) in comparison with pre-lockdown (7.04-7.66%). Bed and rise times were delayed and there was an increased time in bed and sleep onset latency. There was further a decrease in total sleep time and in sleep efficiency during both confinements. The prevalence of clinical insomnia quadrupled during the second wave in comparison with the pre-lockdown situation. Sleep habits were most altered in the younger population, indicating a greater risk for this group to develop a sleep-wake rhythm disorder.


    • 31 January 2023

    Neurocognitive Functioning in Metastatic Cancer Survivors Treated With Immune Checkpoint Blockade: First Results of A Single Center Cohort Study

    by Nathalie Vanlaer, Daphné Kyndt, Sebastien Van Eycken, Jens Tijtgat, Jolien Kessels, Iris Dirven, Manon Vounckx, Bart Neyns, Anne Rogiers